Compare FXNC & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FXNC | EDIT |
|---|---|---|
| Founded | 1907 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 250.1M | 206.0M |
| IPO Year | 2012 | 2016 |
| Metric | FXNC | EDIT |
|---|---|---|
| Price | $26.63 | $2.11 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $4.50 |
| AVG Volume (30 Days) | 62.5K | ★ 1.3M |
| Earning Date | 04-30-2026 | 01-01-0001 |
| Dividend Yield | ★ 2.55% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.35 | N/A |
| Revenue | $7,717,000.00 | ★ $31,937,000.00 |
| Revenue This Year | $7.52 | N/A |
| Revenue Next Year | $4.47 | N/A |
| P/E Ratio | $19.80 | ★ N/A |
| Revenue Growth | 7.40 | ★ 132.64 |
| 52 Week Low | $18.26 | $0.91 |
| 52 Week High | $28.89 | $4.54 |
| Indicator | FXNC | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 46.08 | 56.03 |
| Support Level | $25.35 | $1.94 |
| Resistance Level | $28.89 | $2.76 |
| Average True Range (ATR) | 0.80 | 0.12 |
| MACD | -0.20 | 0.03 |
| Stochastic Oscillator | 2.18 | 97.53 |
First National Corp is a bank holding company of First Bank, which is a commercial bank. Its core offering includes loans, deposits, wealth management, and other products and services. The Company operates through two reportable operating segments: Community Banking and wealth management. The Community Banking segment involves making loans and generating deposits from individuals, businesses, and charitable organizations. Wealth Management Services offers corporate trustee services, trust and estate administration, IRA administration and custody services. Key revenue is generated from Community Banking.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.